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Plasma cell leukemia is a rare, aggressive form of multiple myeloma with the presence of
circulating plasma cells in the peripheral blood. There are two types of plasma cell leukemia,
primary and secondary, depending on if there was previous evidence of multiple myeloma.
The diagnostic criterion of plasma cell leukemia is based on a percentage (>20%) or an absolute number of (≥2 x 109/L) plasma cells in the peripheral circulation. We present the clinical
course of a rare case of secondary plasma cell leukemia in a patient from the time of initial
diagnosis of multiple myeloma, its remission period of about 5 years, and its final progression into refractory secondary plasma cell leukemia. This case report details the patient’s
presenting symptoms, pertinent laboratory and diagnostic imaging findings, and histopathology of peripheral blood and bone marrow. This case report presents a chronological
comparison of key laboratory findings that manifest the progression of multiple myeloma
into secondary plasma cell leukemia. It also offers a brief review of the literature for the
diagnosis and treatment of plasma cell leukemia.
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Introduction

The first case of plasma cell leukemia (PCL)
was identified more than a century ago by
Gluzinski and Reichenstein.1 There are two
types of PCL, primary and secondary. Primary
PCL (PPCL) is diagnosed when there was no
previous evidence of multiple myeloma (MM).
The diagnosis of secondary PCL (SPCL) is
made when previously MM was present, and it
advanced to a relapsed refractory form.1 In the
remainder of this text, the term PCL generically applies to both PPCL and SPCL.
PCL resembles acute leukemia more than MM.
In PCL, there is more systemic infiltration
of the organs and less bone as compared to
MM.2 The incidence of PCL is between 2–4%
of patients with MM.1 Among all cases of PCL,
60–70% are primary, and 30–40% are secondary.1 Secondary conversion to plasma cell leukemia occurs in 1–4% cases of MM.3 In the Unit-

ed States, the incidence of PCL is 0.02–0.03
cases per 100,000 population, accounting for
less than 0.2% of all leukemia cases between
1997–2002.3 The prognosis of PPCL is poor, with
a median survival of 7–11 months.2,3 Survival is
even shorter for SPCL with a median survival of 2–7 months.3,4 There appears to be a 3:2
male to female sex distribution in both PPCL
and SPCL.3 Induction chemotherapy should be
started without delay to minimize the risk of
early death.1,5 PPCL is almost 100% responsive
to chemotherapy and, due to its aggressiveness, exhibits early relapse.2 SPCL has only a
50% response to treatment and culminates
in premature death within months.2 Commonly used chemotherapy for PCL includes
treatment with bortezomib-based regimens
followed by autologous or allogeneic stem cell
transplantation in patients who are appropriate
candidates.1,4-6 The best survival data for PCL
is in patients who received salvage autologous
stem cell transplantation (ASCT) following an
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Table 1. Serum Immunofixation and Serum Protein Electrophoresis.
Initial (MM diagnosed)
SPCL Progression (5 years
post MM diagnosis)
Immunoglobulin G: 700–1400 mg/dL 383 (L)

241 (L)

Immunoglobulin A: 91–414 mg/dL

1294 (H)

4802 (H)

Immunoglobulin M: 40–230 mg/dL

22 (L)

10 (L)

Protein, total: 6.0–8.5 g/dL

6.9

9.5 (H)

Albumin: 3.2–5.6 g/dL

4.1

3.0 (L)

Alpha-1 globulin: 0.1–0.4 g/dL

0.3

0.2

Alpha-2 globulin: 0.4–1.2 g/dL

1.4 (H)

0.6

Beta globulin: 0.6–1.3 g/dL

0.8

5.3 (H)

Gamma globulin: 0.5–1.6 g/dL

0.4 (L)

0.4 (L)

Globulin, Total: 2.0–4.5 g/dL

2.8

6.5 (H)

A/G ratio: 0.7–2.0

1.5

0.5 (L)

M-spike

Not observed

Observed in the beta region

aggressive chemotherapeutic regimen.2,4 The
unfavorable prognostic factors in PCL are the
same as that of MM, but their prevalence is
significantly higher. These risk factors include
elevated β2-microglobulin, low serum albumin,
hypercalcemia, elevated serum lactate-dehydrogenase, poor performance status and
advanced age.2

Case Presentation

Our patient was a 70-year-old male with a
past medical history of hypertension, multiple
myeloma and prostate cancer status post external beam radiation treatment. His prostate
cancer was in remission. About 5 years before
the current presentation, he was diagnosed
with IgA Kappa MM. His initial diagnosis of MM
was confirmed with elevated IgA levels, elevated Kappa light chains, high Kappa/Lambda
light chain ratio with no monoclonal M-spike in
SPEP. (Tables 1 and 2)
Bone marrow flow cytometry revealed 6%

monotypic plasma cells of Kappa type consistent with plasma cell dyscrasia with no
evidence for abnormal myeloid maturation or
increased blast population. (Table 3)
The skeletal survey didn’t reveal any lytic
lesions. Upon initial diagnosis of MM, he received cyclic treatments using bortezomib,
lenalidomide, elotuzumab and zoledronic acid
at standard dosage.7,8 He developed moderate
peripheral neuropathy from bortezomib, and
subsequent treatments with bortezomib were
held. Overall, he had a good response to all
these treatments and remained symptoms and
disease-free for about 5 years since his initial
diagnosis of MM.
In his current clinical presentation, the patient
exhibited symptoms of worsening progression
of back pain, abdominal pain and generalized
weakness over several weeks. The patient’s
family stated that he had increasing cognitive
decline, frailty and irritability. A complete blood

Table 2. Serum Free Light Chain Assay.
Initial (MM diagnosed)

40

SPCL Progression (5 years
post MM diagnosis)

Free Kappa: 3.3–19.4 mg/L

31.26 (H)

1547.5 (H)

Free Lambda: 5.7–26.3 mg/L

6.30

2.4 (L)

Kappa/Lambda ratio: 0.26–1.65 4.96 (H)

644.79 (H)

Comment

IgA monoclonal protein with
Kappa light chain sensitivity

IgA monoclonal protein with
Kappa light chain sensitivity
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Table 3. Flow Cytometry and Skeletal Survey.
Initial (MM diagnosed)

SPCL Progression (5 years post MM
diagnosis)

Flow Cytometry

Bone marrow flow revealed 6%
monotypic plasma cells of Kappa
type consistent with plasma cell
dyscrasia. There was no evidence
of abnormal myeloid maturation
or increased blast population. No
evidence of B-cell or T-cell lymphoproliferative disorder was present

Peripheral smear flow cytometry
revealed circulating monoclonal
plasma cell population 89% of leukocytes, consistent with plasma cell
leukemia/ peripheralized myeloma.

Skeletal Survey

No lytic lesions were seen.

Multiple lesions were noted in the
axial and appendicular skeleton.

count revealed marked anemia with hemoglobin <7.0 g/dL and thrombocytopenia with
platelets <50,000/uL, both of these counts had
significantly declined from his baseline levels
over the previous 5 years. Bone marrow biopsy
revealed 90% plasma cells, and immunohistochemical stain with CD34 revealed a normal
number of blasts.9 (Figure 1) A CD138 confirmed the vast majority of plasma cells.9
Cytogenetic analysis demonstrated a deletion
of the short arm of chromosome 1. We compared several of his key laboratory and imaging
findings from his initial diagnosis of MM to
current presentation: serum immunofixation,
serum-free light chains essay, SPEP, flow cytometry and skeletal survey. The comparison
revealed that his serum IgA levels had increased
about three-fold, SPEP revealed M-spike present in the beta region that was not present
during the initial MM diagnosis. (Table 1,
Figure 2)
His serum Kappa light chain levels increased
by about 50 times, Kappa/Lamba light chain

ratio increased by about 130 times. (Table 2)
Flow cytometry of peripheral blood confirmed
circulating monoclonal plasma cells population
comprising of 89% leukocytes, consistent with
plasma cell leukemia or peripheralized myeloma. (Table 3, Figure 3) The skeletal survey
revealed multiple lesions in the axial and appendicular skeleton. (Table 3)
After the diagnosis of SPCL, in a period of
about 4 months, he was hospitalized multiple
times for symptomatic anemia and neutropenic infections associated with marked pancytopenia. During these hospital admissions, he
was treated for opportunistic infections of the
lung and urinary tract related to febrile neutropenia. He also required frequent red blood
cell and platelet transfusions. Since the onset
of progression to SPCL, his platelet count
stayed in the range of 9,000–47,000/uL despite regular platelet transfusions. (Table 4) His
treatments with elotuzumab were restarted,
and he exhibited no improvements in symptom
progression.7

Figure 1. Bone marrow biopsy of a patient showing a diffuse infiltrate of atypical plasma cells
lacking blastic features.9
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Figure 2. (A) SPEP Initial (MM Diagnosed). M-spike is not present. (B) SPEP at the time of SPCL
diagnosis (five years post MM diagnosis). M-spike is present in the beta region.
During his last hospitalization, the patient had
presented with symptoms of severe respiratory distress and septic shock. He was placed
on mechanical ventilator support due to complications from Pseudomonas pneumonia and
treated with IV antibiotics. His blood cultures
were positive for Candida tropicalis and Pseudomonas. His pancytopenia became worse with
absolute neutrophil count less than 400/uL and
platelet count remaining below 10,000/uL, despite frequent platelet transfusions. (Table 4)

His bone marrow output continued to remain
severely depressed, and he did not respond well
to bone marrow colony-stimulating factors
such as filgrastim. He failed multiple extubation attempts from mechanical ventilation, and
his clinical status deteriorated rapidly, eventually leading to his demise. In summary, the
patient had progressed from MM to SPCL in
nearly five years since the diagnosis of MM and
then rapidly progressed to his death in about 4
months since the diagnosis of SPCL.

Figure 3. Peripheral blood flow cytometry, representative dot plot(s). This study was done at the
time of SPCL diagnosis.
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Table 4. Clinical and pathologic features of primary and SPCL.2 Lab value ranges are noted since
the patient’s diagnosis of SPCL until his death.
Likelihood in PPCL Likelihood in SPCL Present in our patient
Renal Insufficiency

Yes

Yes

Yes@

Extramedullary
deposits

Yes

Yes

Yes. Hepatomegaly, splenomegaly, lymphadenopathy.

Osteolytic lesions

Yes, PPCL < SPCL

Yes

Yes. Osteolytic lesions in skull
and ribs.

Low albumin

Yes

Yes

Yes*

Hypercalcemia

Yes

Yes

Yes%

Pancytopenia

Yes

Yes

Yes#

Monoclonal
gammopathy

Yes

Yes

Yes. IgA gammopathy.

@Creatinine 1.30–2.25 [0.8–1.0 mg/dL]
GFR 29–55 [42–98 L]
*Albumin 1.6–2.2 [3.2–5.6 g/dL]
%Corrected Calcium 11.7–13.6 [8.7–10.5 mg/dL]
#WBC 0.50–1.88 x 103 [4.8–10.8 x 103 /uL]
Hemoglobin 5.2–8.5 [14–17 g/dL]
Platelets 9–47 x 103 [150–450 x 103 /uL]
Absolute Neutrophil Count 0.11–0.51 x 103 [1.8–7.7 x 103 /uL]

Discussion

Plasma cell malignancies include four entities:
classic MM, extramedullary plasmacytoma
without MM, solitary plasmacytoma of bone
and PCL.10 PCL represents between 2–4% of
all plasma cell malignancies, and 0.3% of acute
leukemias.2,10 The median time to leukemic
transformation for patients with MM who
evolve to SPCL is 21 months.3 In the case of
our patient, this transformation was clinically
observed after 58 months since the initial diagnosis of MM. Both PPCL and SPCL patients
present with renal insufficiency, as was the case
with our patient.3 (Table 4) Osteolytic lesions
are more common in the case of SPCL as compared to PPCL.2,3 Our patient had osteolytic
lesions noted in the skull and the ribs. (Table
4) The bone marrow cytogenetic analysis was
remarkable for the presence of 1p deletion. The
deletion of 1p is associated with worse overall
and progression-free survival for patients with
MM.11
The cut off for diagnosis of PCL that is based
on the number of circulating plasma cells is arbitrary.1,3 There are proposals for a lower threshold (i.e., ≥5% peripheral blood plasma cells or an
absolute number ≥0.5×109/L) for early diagnosis

of PCL to initiate timely treatments and improve survival outcomes.1 Both CD38 and CD138
are expressed in MM and PCL.1,2 The principal
immunophenotypic difference between PPCL
and MM is that PPCL tumor cells are less often
positive for CD27, CD56, CD71, CD117 and HLADR, but more often express CD20, CD44, CD45,
CD19 and CD23.2 PCL usually expresses CD20
and has negative CD56 expression.2,10 CD56 is
associated with anchoring plasma cells to bone
marrow.2,12 CD28 is more frequently expressed
in SPCL.1 Genomic and clinical differences
between PCL and MM have been recognized.
P53 and DIS3 mutations are more common in
PPCL and MM, whereas NRAS, KRAS, BRAF
mutations are less frequent in PPCL than in
MM and SPCL.6 Both MM and PPCL have the
following translocations that include chromosome 14: t(11;14), t(14;16) and t(4;14).6 The t(4;14)
mutation predicts sensitivity to treatment with
BCL-2 inhibitor venetoclax, whereas t(11;14)
and t(14;16) are associated with high-risk MM.6
Furthermore, hypodiploidy, 13q deletions, 1p
deletions and 1q gains could define an advanced
stage of plasma cell disease characterized by
poor prognosis and resistance to therapy.2 The
treatment options for PPCL with conventional regimens of VAD (vincristine, doxorubicin,
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dexamethasone) in a combination of alkylating
agents with corticosteroids is found to be inferior compared to novel agents.2,8,13,14 The novel
agents include proteasome inhibitors (bortezomib) and immunomodulatory agents (lenalidomide).2,8,13,14
In PPCL, favorable outcomes of increased
overall and progression-free survival over 12
months are reported with combination regimens, including bortezomib, lenalidomide and
dexamethasone.2,7,8 Stem cell transplant (SCT)
can be considered depending on the patient’s
age and functional status and other clinical
parameters.2 For patients less than the age of
50, allogeneic SCT (AlloSCT), and for patients
over the age of 50, autologous SCT (ASCT)
offer improved treatment outcomes.2 Patients
receiving ASCT had improved overall survival of
34 versus 11 months over those receiving only
chemotherapy.2 AlloSCT is potentially curative
but is associated with high transplant-related
mortality.2 In one study, overall 3-year survival
in ASCT was better than AlloSCT, 64% versus
39%, respectively.2,6
Regarding SPCL treatment, there are limited
case statistics due to the rarity of the disease.
In a case series of nine SPCL patients, who
received the treatment combination of lenalidomide, bortezomib and dexamethasone, had an
overall response rate of 44% and median overall survival of only 5.13 months.2 A recent case
series further investigated the treatment of
SPCL with bortezomib and lenalidomide-containing regimen achieving progression-free
survival of more than 27 months in 2 of 9
patients.6 In a multicenter retrospective study
of 72 SPCL patients, in a median followup of
16.3 months of those patients who received
any treatment for SPCL, had a median overall
survival rate of 4.2 months and a 1-year overall
survival rate of 19%.4 In SPCL, the overall response rate was substantially higher in patients
who received salvage ASCT than those who did
not receive ASCT (93% versus 36%, respectively, p <0.001).4 In SPCL patients AlloSCT is not
indicated.2 In SPCL, platelet count less than
100,000/uL is an independent biological predictor of worse overall survival.4 Both the median
overall survival and the 1-year overall survival rate were worse in patients with platelet
count less than 100,000/uL (median OS: 3.5 vs.
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13.2 months, one-year OS: 8.9% vs. 69.3%, p =
0.0001).4
There is a new emerging class of drugs for
refractory MM and PCL that have shown some
demonstrable benefits. These include venetoclax as a BCL-2 inhibitor, and pomalidomide as
a third-generation immunomodulatory drug,
ixazomib and carfilzomib as second-generation
proteasome inhibitors, daratumumab as an anti-CD38 antibody, novel anti-CD45/anti-CD75
antibodies, BRAF/MEK inhibitors, and CAR-T
therapy using genetically engineered autologous T cells that are programmed to bind
specific antigens on target cells.6

Conclusion

PPCL is a rare disease, and SPCL is even more
unique. PCL is very aggressive with poor survival statistics. Upon initial diagnosis of PCL,
high dose induction chemotherapy should be
started without delay, followed by autologous
or allogeneic stem cell transplantation, depending on the patient’s age and other factors as
applicable. Platelet counts lower than 100,000/
uL are an independent risk factor of poorer
prognosis in SPCL. In our patient, at the time
of SPCL diagnosis, we observed several orders
of magnitude increase in free light chain counts
and ratios with marked differences in gamma
globulin counts from baseline values noted at
the time of MM diagnosis. These laboratory
data could potentially serve as crucial early indicators for the progression of MM into SPCL.
Despite the current armamentarium for the
treatment SPCL, this disease has high mortality and poor overall survival with rapid succession to death within months of diagnosis.
Hence, research for novel agents with higher
efficacy is warranted towards improved treatment outcomes for this difficult and challenging disease process.
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